1. Home
  2. VRAX vs AZTR Comparison

VRAX vs AZTR Comparison

Compare VRAX & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.19

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.17

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
AZTR
Founded
2013
2014
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
1.9M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
VRAX
AZTR
Price
$0.19
$0.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$1.00
$4.00
AVG Volume (30 Days)
191.8K
1.6M
Earning Date
01-01-0001
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.14
52 Week High
$1.43
$1.40

Technical Indicators

Market Signals
Indicator
VRAX
AZTR
Relative Strength Index (RSI) 38.14 38.12
Support Level N/A $0.15
Resistance Level $0.25 $0.32
Average True Range (ATR) 0.02 0.02
MACD 0.00 0.00
Stochastic Oscillator 10.22 18.18

Price Performance

Historical Comparison
VRAX
AZTR

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: